Several categories of drugs directly affect the cerebellum, the brain region responsible for coordinating movement, balance, and motor learning. Alcohol is the most common, but prescription medications like phenytoin and lithium, sedatives like benzodiazepines, and illicit drugs including methamphetamine and cannabis all alter cerebellar function in distinct ways. Some cause temporary impairment that resolves when the drug clears. Others can cause lasting damage.
Alcohol
Alcohol is the single most studied drug when it comes to cerebellar effects. The cerebellum contains Purkinje cells, large neurons that serve as the primary output of the cerebellar cortex. These cells are central to how the brain fine-tunes movement, and alcohol disrupts them through two competing actions at the same time.
On one side, alcohol triggers the release of GABA, the brain’s main inhibitory chemical, at connections feeding into Purkinje cells. This would normally quiet the cells down. On the other side, alcohol directly increases the intrinsic firing rate of the Purkinje cells themselves. The result is a tug-of-war: some cells speed up, others slow down, and the overall pattern of coordinated signaling breaks apart. That disorganized output is what produces the slurred speech, unsteady gait, and poor coordination of intoxication.
With chronic heavy drinking, the damage becomes structural. The cerebellum physically shrinks, a change visible on brain imaging. This is one reason long-term alcohol use can cause a persistent, stumbling gait even during periods of sobriety. The Mayo Clinic lists alcohol as a substance that can make ataxia (loss of coordination) worse and recommends avoiding it entirely if you already have cerebellar problems.
Phenytoin (Anti-Seizure Medication)
Phenytoin, sold under the brand name Dilantin, is one of the most widely prescribed anti-seizure medications globally and one of the best-documented causes of drug-induced cerebellar damage. At therapeutic doses it generally works without problems, but toxic levels or prolonged use can lead to cerebellar atrophy, meaning the cerebellum physically loses tissue over time.
In one documented case, a 23-year-old woman taking 300 mg daily for post-traumatic seizures developed severe cerebellar atrophy and significant neurological impairment. While this is considered an uncommon side effect, it is well-established in the medical literature and tends to present with progressive unsteadiness, difficulty with fine motor tasks, and slurred speech. The encouraging finding is that in some cases, cerebellar function partially recovers after the drug is stopped, though recovery is not guaranteed.
Lithium
Lithium, commonly used to treat bipolar disorder, can cause devastating cerebellar damage when blood levels climb too high. Normal therapeutic levels are tightly controlled, but dehydration, kidney changes, or accidental overdose can push levels into the danger zone.
At mildly elevated levels, lithium causes a benign tremor. As levels rise further, symptoms escalate to coarse tremor, slurred speech, loss of coordination, seizures, and eventually coma. In most cases, stopping the drug or lowering the dose reverses these effects. But in a subset of patients, the cerebellar damage persists permanently, a condition researchers have named the Syndrome of Irreversible Lithium-Effectuated Neurotoxicity, or SILENT. To qualify for this diagnosis, neurological problems must last beyond two months after lithium is completely out of the system.
Case reports illustrate how severe this can be. One patient whose lithium level reached 4.42 mEq/L (well above the typical therapeutic range of 0.6 to 1.2) still had an unsteady gait, jerky eye movements, tremors, and disarticulate speech six months later, despite lithium levels dropping below 0.2 and normal results on all other tests. Another patient with a level of 2.52 mEq/L still had a clumsy, ataxic gait and obvious limb incoordination a full year afterward. Persistent cerebellar dysfunction is the most commonly reported long-term consequence of lithium toxicity.
Benzodiazepines
Benzodiazepines like diazepam (Valium), lorazepam (Ativan), and alprazolam (Xanax) work by enhancing GABA signaling throughout the brain, including the cerebellum. The cerebellum uses GABA-based inhibition to fine-tune the timing of movements, and flooding this system with extra inhibitory signals produces the characteristic sedation and motor slowing these drugs cause.
Interestingly, the cerebellum’s relationship with benzodiazepines is more complex than in other brain regions. Certain cells in the cerebellum, particularly granule cells, contain receptor subtypes that are actually insensitive to classical benzodiazepines like diazepam. This means the drug’s effects on the cerebellum are somewhat selective, hitting some cell populations harder than others. The practical result is temporary: impaired balance, slower reaction times, and reduced coordination that resolve as the drug wears off. Long-term structural cerebellar damage from benzodiazepines alone is not well documented, unlike with alcohol or phenytoin.
Cannabis (THC)
The cerebellar cortex contains the highest density of CB1 receptors in the entire brain. CB1 is the receptor that THC, the psychoactive compound in marijuana, binds to. Under normal conditions, these receptors are part of the brain’s own endocannabinoid system: Purkinje cells release natural cannabis-like molecules that travel backward to connecting nerve terminals and temporarily dial down incoming signals from parallel fibers and climbing fibers. This fine-tunes how the cerebellum processes motor information.
When THC floods these receptors, it overrides that precise signaling system. The result is impaired locomotor control, slower reaction times, and reduced motor coordination. Despite the extremely high concentration of CB1 receptors in the cerebellum, mice genetically engineered to lack these receptors don’t show severe cerebellar deficits in everyday movement, which suggests the endocannabinoid system is more important for motor learning and adaptation than for basic coordination. This aligns with what cannabis users experience: difficulty with novel or complex motor tasks rather than an inability to walk.
Methamphetamine and Other Stimulants
Long-term methamphetamine use causes measurable structural changes in the cerebellum, including reduced gray matter volume. But the damage goes beyond structure. Brain imaging studies show that people with methamphetamine dependence have disrupted communication between the cerebellum and several major brain networks, including those responsible for executive control, emotional regulation, and sensory-motor processing. The worse the addiction severity, the more disrupted the connection between specific cerebellar regions and areas involved in self-awareness and memory.
Some of this damage appears partially reversible. People who maintained six months of abstinence showed gains in cerebellar gray matter volume compared to active users. The cerebellum’s role in addiction itself is an active area of investigation. Animal studies show widespread nerve fiber connections between the cerebellum and the brain’s reward circuitry, and imaging studies consistently show the cerebellum activating alongside reward-related brain areas when people with addiction are shown drug-related images.
Mercury and Heavy Metals
While not a recreational or prescription drug, mercury exposure deserves mention because its effects on the cerebellum are among the most specific and devastating of any toxic substance. Methylmercury, the form found in contaminated fish and the cause of Minamata disease, selectively destroys granule cells in the cerebellum while largely sparing Purkinje cells. This is unusual because most other cerebellar toxins, including alcohol, primarily target Purkinje cells.
The mechanism involves a chain reaction: methylmercury first causes small-scale damage to granule cells, which triggers immune cells to infiltrate the area. These immune cells then release inflammatory molecules that drive further granule cell death. Granule cells are vulnerable both to the direct toxic effects of methylmercury and to the inflammatory signals that follow, creating a destructive cycle. The clinical result is severe, often irreversible ataxia.
How Cerebellar Damage Is Identified
Regardless of the cause, drug-induced cerebellar damage produces a recognizable set of symptoms: unsteady gait, poor coordination of the arms and legs, slurred or scanning speech, and abnormal eye movements. A healthcare provider will typically check your vision, balance, coordination, and reflexes during a neurological exam. Specific tests like the finger-to-nose test and rapid alternating hand movements help isolate cerebellar function.
MRI is the primary imaging tool. It can reveal shrinkage of the cerebellum and help rule out other causes like stroke or tumors. In some cases, a spinal tap may be performed to check for infection or inflammation. The most important diagnostic step, though, is a thorough medication and substance use history, since identifying and stopping the offending drug is the first and most effective treatment for most forms of drug-induced cerebellar dysfunction.